ICE said on Thursday that all 42.25 million shares offered were sold, representing 60.36 percent of the capital, implying a market value of 1.4 billion euros ($1.91 billion) for all of the company.
"Equity markets are at the bottom of a cycle right now in terms of trading activity. Stock prices have been rising but there's no volume," said David Thebault, head of quantitative sales trading at Global Equities, in Paris.
"In this context, it's hard to get excited about Euronext's business, the potential growth is tiny. There are better investment ideas elsewhere, in the biotech space for instance."
Read MoreEuronext trading start delayed due to glitch
ICE acquired NYSE Euronext in a $11 billion deal last year. The U.S. exchanges group committed to spinning off Euronext at the time.
Euronext—which has been battling with competitors such as BATS Chi-X Europe to preserve its market share in Europe—has said it plans to return to revenue growth over the next three years, following declines in both 2012 and 2013.
Using a projection from Euronext's first-quarter net income of $36 million over the full year, a share price of 19.40 euros would imply a price-to-earnings (P/E) ratio of about 12.8, according to Reuters calculations.
This compares with P/E ratios of 18 for the shares of UK peer London Stock Exchange Group and 14.8 for German rival Deutsche Boerse, according to Thomson Reuters data.
A group of European institutional investors bought a 33.4 percent stake in Euronext at a 4 percent discount to the IPO price, or 19.20 euros a share, in a move designed to allay local regulators' concerns that the pan-European bourse could be snapped up by another foreign firm.
ABN AMRO Bank, JPMorgan and Societe Generale acted as joint global coordinators for the IPO.